Immune checkpoint inhibitors (ICIs) are drugs growingly employed in the treatment of cancers, but there are still uncertainties about their possible role in the risk of developing nontuberculous mycobacteria (NTM) infections. To understand this, we performed a systematic review of the literature including studies published between 20 June 2012 and 20 June 2022 which described the occurrence of NTM infections among patients treated with ICIs. Overall, we included seven studies describing nine patients with NTM infection occurring during ICIs therapy. NTM infections occurring during ICIs therapy are mainly caused by germs belonging to the Mycobacterium avium complex, involve primarily the lungs, on average 1 year after the start of treatment, and are not associated with immunosuppressive treatments.

Non-tuberculous mycobacterial infections during cancer therapy with immune checkpoint inhibitors: a systematic review / A. Lombardi, A. Gramegna, M. Ori, C. Azzarà, F.B.A. Blasi, A. Gori. - In: ERJ OPEN RESEARCH. - ISSN 2312-0541. - 8:4(2022), pp. 00364-2022.1-00364-2022.17. [10.1183/23120541.00364-2022]

Non-tuberculous mycobacterial infections during cancer therapy with immune checkpoint inhibitors: a systematic review

A. Lombardi
Primo
;
A. Gramegna
Secondo
;
F.B.A. Blasi
Penultimo
;
A. Gori
Ultimo
2022

Abstract

Immune checkpoint inhibitors (ICIs) are drugs growingly employed in the treatment of cancers, but there are still uncertainties about their possible role in the risk of developing nontuberculous mycobacteria (NTM) infections. To understand this, we performed a systematic review of the literature including studies published between 20 June 2012 and 20 June 2022 which described the occurrence of NTM infections among patients treated with ICIs. Overall, we included seven studies describing nine patients with NTM infection occurring during ICIs therapy. NTM infections occurring during ICIs therapy are mainly caused by germs belonging to the Mycobacterium avium complex, involve primarily the lungs, on average 1 year after the start of treatment, and are not associated with immunosuppressive treatments.
Settore MED/17 - Malattie Infettive
Article (author)
File in questo prodotto:
File Dimensione Formato  
23120541.00364-2022.full.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 548.77 kB
Formato Adobe PDF
548.77 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/945528
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 0
social impact